New drugs

New results from the final stage of extensive clinical trials for the anti-amyloid immunotherapy drug “donanemab” have confirmed significant benefits for people in the early stage of Alzheimer’s disease.

The drug, which was shown to slow cognitive and functional decline by 22%, could receive regulatory approval for use in the USA by the end of the year.  Applications by the manufacturer Eli Lilly to distribute donanemab in the UK and Europe are likely to follow.

Donenemab was more effective during the earliest stages of symptomatic Alzheimer’s disease and also in people with mild cognitive impairment (MCI), slowing decline by 60% in these groups.  There was an overall 40% slowing in decline of everyday activities such as driving, doing hobbies and managing finances.  In a significant number of cases, there was zero progression in disease symptoms over the 18 months of the trial.

If US regulatory approval is forthcoming, donanemab will join two other recently discovered monoclonal antibody drugs licensed for distribution there, lecanemab and aducanumab.  But aducanumab did not win approval from the UK regulatory agency and a decision on lecanemab is not expected here until next year.

“The treatment effect is modest [for donanemab], as is the case for many first-generation drugs, and there are risks of serious side effects that need to be fully scrutinised before donanemab can be marketed and used,” said Dr Susan Kohlhaas, research director at Alzheimer’s Research UK.  “However, this news underlines the urgency of preparing the NHS to make these treatments available should regulators deem them safe and effective.”

Major investment will be needed in early diagnosis, including PET scanners, if Alzheimer’s is to be treated.  At present, only 2% of people would be diagnosed early enough to benefit from donanemab.

Similar Posts

  • NAPA 25th Anniversary Walk

    On Wednesday May 25th NAPA will celebrate their 25th Anniversary by leading a National Wellbeing Walk through Old Amersham, Buckinghamshire. The NAPA Team will be joined by residents from one of their local member Care Home Groups, The Fremantle Trust.  All 3,500 NAPA Member care services and partner organisations are invited to walk in solidarity and raise…

  • Dementia 100 Pathway Self-assessment Tool launched 

    The Dementia 100 Pathway Self-assessment Tool has been launched.  The Tool has been developed through collaboration between NHS Midlands and Lancashire’s Improvement Unit, the Department of Health and Social Care (DHSC) and NHS England (NHSE). It’s been supported by the National Collaborating Centre for Mental Health, the Alzheimer’s Society and Dementia UK.   Dementia 100 is…

  • Young dementia

    Young Dementia Network (YDN) has created a short animation explaining what YDN is, what it does and how to join up. The narrator in the “What is the Young Dementia Network” video, available on the YDN website and on its YouTube channel, talks from the perspective of someone with young onset dementia and the typical…

  • Leadership training

    A new training programme designed to develop leadership skills among people from black, Asian and ethnic minority backgrounds working in social care has been launched by Skills for Care. The Forefront Programme is a new suite of digital modules which is intended to build participants’ confidence in improving equality, diversity and inclusion in their organisation. Find out more…

  • Dementia and End of Life Choices booklet

    The Scottish Dementia Alumni, a group of campaigning friends in Scotland who each have a diagnosis of dementia, have published their latest booklet ‘Dementia and End of Life Choices’.  The Scottish Dementia Alumni says of their new publication:  “This booklet was an emotional creation, as we all needed to confront challenging concepts and our own…

  • In Wonderland

    Winchester care home St Catherine’s View celebrated its 10th anniversary with a “Hatter’s tea party” and a wardrobe of fancy dress costumes.  Among guests at the Alice in Wonderland-themed party was “Alice” herself, clinical lead Hayley Geddes, who is pictured with resident Christina Millest. “Our Hatter’s tea party was a lovely opportunity to celebrate and we…